{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T02:04:11Z","timestamp":1784081051827,"version":"3.55.0"},"reference-count":311,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Pancreatic cancer remains one of the most aggressive and lethal malignancies, characterized by late-stage diagnosis, profound molecular heterogeneity, and limited responsiveness to conventional cytotoxic therapies. Recent advances in molecular diagnostics and biomarker-driven treatment stratification have accelerated the development of precision therapeutic approaches aimed at improving outcomes in selected patient populations. This review highlights three mechanistically distinct yet complementary therapeutic strategies that illustrate the evolving landscape of personalized pancreatic cancer management. Adagrasib represents targeted inhibition of oncogenic KRAS G12C signaling, reflecting recent progress in directly targeting historically \u201cundruggable\u201d driver mutations. Dostarlimab illustrates the tissue-agnostic application of immune checkpoint blockade in pancreatic cancers harboring mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H), highlighting the growing importance of biomarker-defined immunotherapy-responsive subsets despite the limited pancreatic cancer-specific clinical evidence currently available. Trastuzumab deruxtecan represents a next-generation HER2-directed antibody\u2013drug conjugate (ADC) and demonstrates the potential of HER2-targeted therapy in the small subgroup of patients with HER2-positive pancreatic cancer, although the available evidence is derived primarily from basket trials and tumor-agnostic clinical development. Collectively, these therapeutic approaches underscore the expanding role of biomarker-guided treatment strategies integrating targeted inhibition, immunotherapy, and precision cytotoxic payload delivery. This review summarizes the molecular rationale, available clinical evidence, therapeutic limitations, and resistance mechanisms associated with these approaches while discussing emerging directions in translational research, rational combination strategies, liquid biopsy applications, and precision oncology that may further refine individualized treatment algorithms for pancreatic cancer.<\/jats:p>","DOI":"10.3390\/jcm15145521","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T01:05:58Z","timestamp":1784077558000},"page":"5521","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Precision Therapeutics in Pancreatic Cancer: Emerging Targeted, Immune, and Antibody\u2013Drug Conjugate Strategies Exemplified by Adagrasib, Dostarlimab, and Trastuzumab Deruxtecan"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3902-2744","authenticated-orcid":false,"given":"Piotr","family":"Kawczak","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University of Gda\u0144sk, 80-416 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7775-5562","authenticated-orcid":false,"given":"Katarzyna","family":"Kawczak","sequence":"additional","affiliation":[{"name":"PwC Advisory sp. z o.o., sp.k., Aleja Grunwaldzka 472C, 80-309 Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6468-1974","authenticated-orcid":false,"given":"Tomasz","family":"B\u0105czek","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University of Gda\u0144sk, 80-416 Gdansk, Poland"},{"name":"Department of Nursing and Medical Rescue, Institute of Health Sciences, Pomeranian University in S\u0142upsk, 76-200 Slupsk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"ref_1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","article-title":"Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes","volume":"24","author":"McGuigan","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(19)30456-5","article-title":"Progress in cancer survival, mortality, and incidence in seven high-income countries 1995\u20132014 (ICBP SURVMARK-2): A population-based study","volume":"20","author":"Arnold","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0140-6736(10)62307-0","article-title":"Pancreatic cancer","volume":"378","author":"Vincent","year":"2011","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Ervin","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.20.01364","article-title":"Metastatic pancreatic cancer: ASCO guideline update","volume":"38","author":"Sohal","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1136\/gutjnl-2015-309304","article-title":"Stromal biology and therapy in pancreatic cancer: A changing paradigm","volume":"64","author":"Neesse","year":"2015","journal-title":"Gut"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.trecan.2018.04.001","article-title":"Immunotherapy and prevention of pancreatic cancer","volume":"4","author":"Morrison","year":"2018","journal-title":"Trends Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","article-title":"Challenges and opportunities for pancreatic cancer immunotherapy","volume":"38","author":"Bear","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","article-title":"Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: A retrospective analysis of the Know Your Tumor registry trial","volume":"21","author":"Pishvaian","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41575-019-0109-y","article-title":"Molecular subtypes of pancreatic cancer","volume":"16","author":"Collisson","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_17","first-page":"123","article-title":"Pancreatic cancer: Current research and future directions","volume":"1865","author":"Falasca","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-020-00958-3","article-title":"Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma","volume":"13","author":"Qian","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5152\/tjg.2024.24544","article-title":"Pancreatic cancer: Current concepts, trends, and future directions","volume":"36","author":"Wenzel","year":"2024","journal-title":"Turk. J. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Schlick, K., Kiem, D., and Greil, R. (2021). Recent advances in pancreatic cancer: Novel prognostic biomarkers and targeted therapy\u2014A review of the literature. Biomolecules, 11.","DOI":"10.3390\/biom11101469"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.soc.2025.03.002","article-title":"Precision oncology in pancreatic cancer and future treatment directions","volume":"35","year":"2026","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41575-019-0245-4","article-title":"Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer","volume":"17","author":"Buscail","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1158\/1078-0432.CCR-17-3099","article-title":"Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: Challenges and recommendations","volume":"24","author":"Hu","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1053\/j.gastro.2019.02.037","article-title":"Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers","volume":"156","author":"Singhi","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/bjc.2014.418","article-title":"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers","volume":"111","author":"Golan","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"101783","DOI":"10.1016\/j.bpg.2021.101783","article-title":"Hereditary pancreatic cancer","volume":"58\u201359","author":"Klatte","year":"2022","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.21037\/cco-2025-1-170","article-title":"Claudin 18.2 testing in gastroesophageal and pancreatobiliary cancers: Current status, clinical implications and challenges","volume":"15","author":"Lee","year":"2026","journal-title":"Chin. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1245\/s10434-020-09367-9","article-title":"Landmark series: Immunotherapy and targeted therapy for pancreatic cancer","volume":"28","author":"Rocha","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1017\/erm.2021.26","article-title":"Opportunities and challenges in targeted therapy and immunotherapy for pancreatic cancer","volume":"23","author":"Cao","year":"2021","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: Is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"a031435","DOI":"10.1101\/cshperspect.a031435","article-title":"KRAS: The critical driver and therapeutic target for pancreatic cancer","volume":"8","author":"Waters","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRAS G12C mutation","volume":"41","author":"Yaeger","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"107886","DOI":"10.1016\/j.lungcan.2024.107886","article-title":"The next-generation KRAS inhibitors: What comes after sotorasib and adagrasib?","volume":"194","author":"Oya","year":"2024","journal-title":"Lung Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"799","DOI":"10.32604\/or.2024.045356","article-title":"Targeting KRAS in pancreatic cancer","volume":"32","author":"Stickler","year":"2024","journal-title":"Oncol. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","article-title":"Targeting KRAS in cancer","volume":"30","author":"Singhal","year":"2024","journal-title":"Nat. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J. Immunother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Shiu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","article-title":"The tumour microenvironment in pancreatic cancer\u2014Clinical challenges and opportunities","volume":"17","author":"Ho","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-024-01561-6","article-title":"Current and future immunotherapeutic approaches in pancreatic cancer treatment","volume":"17","author":"Farhangnia","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): A multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","article-title":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): A multicentre, open-label, phase 2 trial","volume":"22","author":"Siena","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1158\/2159-8290.CD-20-0215","article-title":"HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers","volume":"10","author":"Li","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13148-016-0286-2","article-title":"Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma","volume":"8","author":"Henriksen","year":"2016","journal-title":"Clin. Epigenet."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2129884","DOI":"10.1080\/08941939.2022.2129884","article-title":"Pancreatic cancer: A review of current treatment and novel therapies","volume":"36","author":"Kolbeinsson","year":"2023","journal-title":"J. Investig. Surg."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.3390\/curroncol31090385","article-title":"Systemic therapy for metastatic pancreatic cancer\u2014Current landscape and future directions","volume":"31","author":"Netto","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41571-025-01019-9","article-title":"Improving outcomes of patients with pancreatic cancer","volume":"22","author":"Dreyer","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.3748\/wjg.v24.i19.2047","article-title":"Challenges in diagnosis of pancreatic cancer","volume":"24","author":"Zhang","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1533033820962117","DOI":"10.1177\/1533033820962117","article-title":"Pancreatic cancer: A review of risk factors, diagnosis, and treatment","volume":"19","author":"Zhao","year":"2020","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: Mission possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41568-021-00418-1","article-title":"Pancreatic cancer evolution and heterogeneity: Integrating omics and clinical data","volume":"22","author":"Connor","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-023-01839-y","article-title":"Adagrasib: First approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13045-024-01631-9","article-title":"RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms","volume":"17","author":"Yang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Krupa, K., Fudalej, M., W\u0142oszek, E., Miski, H., Badowska-Kozakiewicz, A.M., M\u0119kal, D., Budzik, M.P., Czerw, A., and Depta\u0142a, A. (2025). Treatment of KRAS-mutated pancreatic cancer: New hope for the patients?. Cancers, 17.","DOI":"10.3390\/cancers17152453"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"17588359261432058","DOI":"10.1177\/17588359261432058","article-title":"Emerging precision therapeutics for pancreatic ductal adenocarcinoma: KRAS and beyond","volume":"18","author":"Misirian","year":"2026","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s11912-023-01436-y","article-title":"Resistance to KRAS G12C Inhibition in Non-Small Cell Lung Cancer","volume":"25","author":"Ricciotti","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRAS G12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cell.2018.01.006","article-title":"Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor","volume":"172","author":"Janes","year":"2018","journal-title":"Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41571-018-0105-0","article-title":"Therapeutic strategies to target RAS-mutant cancers","volume":"15","author":"Ryan","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3390\/curroncol31040150","article-title":"KRAS: Biology, inhibition, and mechanisms of inhibitor resistance","volume":"31","author":"Ash","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1038\/s41467-020-19288-6","article-title":"Immune modulatory effects of oncogenic KRAS in cancer","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1158\/2159-8290.CD-24-0489","article-title":"Combined KRAS inhibition and immune therapy generates durable complete responses in an autochthonous PDAC model","volume":"15","author":"Liu","year":"2025","journal-title":"Cancer Discov."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2174\/0109298673258913231019113814","article-title":"A new dawn for targeted cancer therapy: Small molecule covalent binding inhibitor targeting K-Ras (G12C)","volume":"32","author":"Li","year":"2025","journal-title":"Curr. Med. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"117626","DOI":"10.1016\/j.ejmech.2025.117626","article-title":"Synthetic approaches and clinical application of KRAS inhibitors for cancer therapy","volume":"291","author":"Jiang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.21.02752","article-title":"First-in-human phase I\/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRAS G12C solid tumors (KRYSTAL-1)","volume":"40","author":"Ou","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e2300447","DOI":"10.1200\/PO.23.00447","article-title":"Safety and intracranial activity of adagrasib in patients with KRAS G12C-mutated non-small-cell lung cancer and untreated CNS metastases in the KRYSTAL-1 trial: A case series","volume":"8","author":"Bernstein","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/2159-8290.CD-24-0217","article-title":"Efficacy and safety of adagrasib plus cetuximab in patients with KRAS G12C-mutated metastatic colorectal cancer","volume":"14","author":"Yaeger","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41392-025-02473-8","article-title":"Targeting KRAS mutations: Orchestrating cancer evolution and therapeutic challenges","volume":"10","author":"Choucair","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"11795549251331759","DOI":"10.1177\/11795549251331759","article-title":"Potency and safety of KRAS G12C inhibitors in solid tumors: A systematic review","volume":"19","author":"Laraqui","year":"2025","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/mc.23908","article-title":"Differential response and resistance to KRAS-targeted therapy","volume":"64","author":"Liu","year":"2025","journal-title":"Mol. Carcinog."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS G12C inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1200\/JCO.22.00562","article-title":"Expanding the arsenal of clinically active KRAS G12C inhibitors","volume":"40","author":"Arbour","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"101591","DOI":"10.1016\/j.esmoop.2023.101591","article-title":"Cracking KRAS G12C across all solid tumors: The new kid on the block for tissue-agnostic precision medicine","volume":"8","author":"Bhamidipati","year":"2023","journal-title":"ESMO Open"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.21037\/tcr-23-1629","article-title":"KRAS G12C inhibitors: Also a promising new targeted therapy in advanced pancreatic adenocarcinoma?","volume":"12","author":"Muller","year":"2023","journal-title":"Transl. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e001925","DOI":"10.1136\/bmjgast-2025-001925","article-title":"Actionable mutations in pancreatic cancer: Where targeted therapies are making a difference","volume":"12","author":"Fivaz","year":"2025","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1158\/2159-8290.CD-18-0275","article-title":"Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine","volume":"8","author":"Aguirre","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRAS G12C inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-19-3523","article-title":"Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS G12C inhibition","volume":"26","author":"Ryan","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e20201414","DOI":"10.1084\/jem.20201414","article-title":"SHP2 inhibition diminishes KRAS G12C cycling and promotes tumor microenvironment remodeling","volume":"218","author":"Fedele","year":"2021","journal-title":"J. Exp. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","article-title":"The current state of the art and future trends in RAS-targeted cancer therapies","volume":"19","author":"Punekar","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1158\/2159-8290.CD-19-0597","article-title":"Tumor microenvironment remodeling enables bypass of oncogenic KRAS dependency in pancreatic cancer","volume":"10","author":"Hou","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"100796","DOI":"10.1016\/j.drup.2021.100796","article-title":"Anticancer drug resistance: An update and perspective","volume":"59","author":"Nussinov","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","article-title":"KRAS inhibitors: Resistance drivers and combinatorial strategies","volume":"11","author":"Isermann","year":"2025","journal-title":"Trends Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(21)00605-7","article-title":"Sotorasib for previously treated colorectal cancers with KRAS G12C mutation (CodeBreaK100): A prespecified analysis of a single-arm, phase 2 trial","volume":"23","author":"Fakih","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"108889","DOI":"10.1016\/j.pharmthera.2025.108889","article-title":"Recent advances in therapeutic targeting of the KRAS pathway in cancer","volume":"273","author":"Hitchen","year":"2025","journal-title":"Pharmacol. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a noncovalent, potent, and selective KRAS G12D inhibitor","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Bannoura, S.F., Khan, H.Y., and Azmi, A.S. (2022). KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1013902"},{"key":"ref_99","first-page":"391","article-title":"Glimmers of hope for targeting oncogenic KRAS-G12D","volume":"30","author":"Tang","year":"2023","journal-title":"Cancer Gene Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41589-024-01565-w","article-title":"Strain-release alkylation of Asp12 enables mutant selective targeting of K-Ras-G12D","volume":"20","author":"Zheng","year":"2024","journal-title":"Nat. Chem. Biol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12943-025-02288-9","article-title":"ADT-1004: A first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma","volume":"24","author":"Bandi","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","article-title":"Anti-tumor efficacy of a potent and selective non-covalent KRAS G12D inhibitor","volume":"28","author":"Hallin","year":"2022","journal-title":"Nat. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1158\/1535-7163.MCT-25-0022","article-title":"Activity of direct KRAS(G12C) inhibitors in preclinical models of pediatric cancer","volume":"25","author":"Price","year":"2026","journal-title":"Mol. Cancer Ther."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Sianoya, A.C., Zuo, Y., Pagba, C.V., Jakubec, J.L., Planque, S.A., Frost, J.A., Medina, P.M.B., and Gorfe, A.A. (Mol. Cancer Ther., 2026). MRTX1133 suppresses ERK signaling but elicits context-dependent antiproliferative responses in KRAS(G12C) cancer cells, Mol. Cancer Ther., online ahead of print.","DOI":"10.1158\/1535-7163.MCT-25-1087"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1080\/14796694.2025.2524311","article-title":"Adagrasib in the treatment of colorectal cancer","volume":"21","author":"Haddad","year":"2025","journal-title":"Future Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1177\/10600280231197459","article-title":"Targeted therapies for previously \u201cundruggable\u201d KRAS-mutated non-small cell lung cancer: A review of sotorasib and adagrasib","volume":"58","author":"Mausey","year":"2024","journal-title":"Ann. Pharmacother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS G12C Mutation","volume":"387","author":"Riely","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/COC.0000000000001249","article-title":"Clinical Outcomes and Safety Profile of Adagrasib in KRAS G12C-Mutated Solid Tumors: A Single-Arm Meta-Analysis","volume":"49","author":"Ahmad","year":"2026","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_109","unstructured":"(2026, May 15). Krazati (Adagrasib) Prescribing Information. U.S. Food and Drug Administration, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216340s005lbl.pdf."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1200\/JCO.2022.40.16_suppl.9002","article-title":"KRYSTAL-1: Updated Activity and Safety of Adagrasib (MRTX849) in Patients with Unresectable or Metastatic Pancreatic Cancer (PDAC) and Other Gastrointestinal (GI) Tumors Harboring a KRAS G12C Mutation","volume":"40","author":"Spira","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_111","unstructured":"(2026, May 15). Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients. NIH. National Library of Medicine. National Center for Biotechnology Information. ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05634525."},{"key":"ref_112","unstructured":"(2026, May 15). A Study of BMS-986466 with Adagrasib with or Without Cetuximab in Participants with Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors. NIH. National Library of Medicine. National Center for Biotechnology Information. ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06024174."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: A common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/gutjnl-2020-320726","article-title":"Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: Histology, molecular pathology and clinical implications","volume":"70","author":"Luchini","year":"2021","journal-title":"Gut"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1158\/1541-7786.MCR-17-0735","article-title":"Landscape of tumor mutation load, mismatch repair deficiency, and PD-L1 expression in a large patient cohort of gastrointestinal cancers","volume":"16","author":"Salem","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Costa, B., and Vale, N. (2022). Dostarlimab: A review. Biomolecules, 12.","DOI":"10.3390\/biom12081031"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1177\/10781552241265058","article-title":"Dostarlimab: A promising new PD-1 inhibitor for cancer immunotherapy","volume":"30","author":"Farzeen","year":"2024","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"104374","DOI":"10.1016\/j.critrevonc.2024.104374","article-title":"Dostarlimab: Review on success story and clinical trials","volume":"198","author":"Yadav","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Kciuk, M., Wanke, K., Kruczkowska, W., Marciniak, B., and Kontek, R. (2025). Focus on PD-1\/PD-L1-targeting antibodies in colorectal cancer: Are there options beyond dostarlimab, nivolumab, and pembrolizumab? A comprehensive review. Molecules, 30.","DOI":"10.3390\/molecules30132686"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"103577","DOI":"10.1016\/j.drudis.2023.103577","article-title":"Promise of Dostarlimab in Cancer Therapy: Advancements and Cross-Talk Considerations","volume":"28","author":"Babar","year":"2023","journal-title":"Drug Discov. Today"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e003777","DOI":"10.1136\/jitc-2021-003777","article-title":"Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient\/microsatellite instability-high (dMMR\/MSI-H) or proficient\/stable (MMRp\/MSS) endometrial cancer: Interim results from GARNET\u2014A phase I, single-arm study","volume":"10","author":"Oaknin","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e2341165","DOI":"10.1001\/jamanetworkopen.2023.41165","article-title":"Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: A nonrandomized controlled trial","volume":"6","author":"Berton","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.cpt.2023.10.003","article-title":"Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer","volume":"2","author":"Shukla","year":"2023","journal-title":"Cancer Pathog. Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s40199-025-00564-z","article-title":"Efficacy of dostarlimab in recurrent or advanced mismatch repair-deficient endometrial cancer as a single-agent therapy: A systematic review and meta-analysis","volume":"33","author":"Rezaei","year":"2025","journal-title":"Daru"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.2217\/fon-2021-0598","article-title":"Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer","volume":"17","author":"Oaknin","year":"2021","journal-title":"Future Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/carcin\/bgae066","article-title":"Redefining pancreatic cancer management with tumor-agnostic precision medicine","volume":"45","author":"Reddy","year":"2024","journal-title":"Carcinogenesis"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.soc.2023.12.001","article-title":"Tissue-agnostic cancer therapy approvals","volume":"33","author":"Gouda","year":"2024","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.32604\/or.2025.067791","article-title":"Advances in tissue-agnostic targeting in cancer therapeutics: Current approvals, challenges, and future directions","volume":"33","author":"Rubinstein","year":"2025","journal-title":"Oncol. Res."},{"key":"ref_132","unstructured":"(2026, May 18). FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Recurrent or Advanced Solid Tumors. U.S. Food and Drug Administration, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1001\/jamaoncol.2020.4515","article-title":"Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: A nonrandomized phase 1 clinical trial","volume":"6","author":"Oaknin","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.3390\/curroncol29080413","article-title":"An exceptional response to dostarlimab in mismatch repair deficient, microsatellite instability-high and platinum refractory endometrial cancer","volume":"29","author":"Bartoletti","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_135","first-page":"325","article-title":"A phase two, single-arm, open-label study with dostarlimab monotherapy in participants with untreated stage II\/III dMMR\/MSI-H locally advanced rectal cancer (AZUR-1)","volume":"24","author":"Cercek","year":"2025","journal-title":"Clin. Colorectal Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: A phase 2 randomized clinical trial","volume":"5","author":"Oh","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1158\/1078-0432.CCR-20-0099","article-title":"Open-label, phase I study of nivolumab combined with nab-paclitaxel plus gemcitabine in advanced pancreatic cancer","volume":"26","author":"Wainberg","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Kabacaoglu, D., Ciecielski, K.J., Ruess, D.A., and Alg\u00fcl, H. (2018). Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: Current limitations and future options. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01878"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s00262-024-03632-6","article-title":"Clinical immunotherapy in pancreatic cancer","volume":"73","author":"Ye","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.str.2017.06.011","article-title":"Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1\/PD-L2","volume":"25","author":"Zak","year":"2017","journal-title":"Structure"},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Lee, H.T., Lee, S.H., and Heo, Y.-S. (2019). Molecular interactions of antibody drugs targeting PD-1, PD-L1, and CTLA-4 in immuno-oncology. Molecules, 24.","DOI":"10.3390\/molecules24061190"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbrc.2022.02.026","article-title":"Molecular basis of PD-1 blockade by dostarlimab, the FDA-approved antibody for cancer immunotherapy","volume":"599","author":"Park","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s10637-017-0525-1","article-title":"Phase Ib\/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma","volume":"36","author":"Weiss","year":"2018","journal-title":"Investig. New Drugs"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1053\/j.gastro.2018.12.038","article-title":"Broadening the impact of immunotherapy to pancreatic cancer: Challenges and opportunities","volume":"156","author":"Balachandran","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1470-2045(20)30532-5","article-title":"CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: An open-label, multicentre, phase 1b study","volume":"22","author":"Varadhachary","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: Current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Shebbo, S., Binothman, N., Darwaish, M., Niaz, H.A., Abdulal, R.H., Borjac, J., Hashem, A.M., and Mahmoud, A.B. (2024). Redefining the battle against colorectal cancer: A comprehensive review of emerging immunotherapies and their clinical efficacy. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1350208"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2178220","DOI":"10.1080\/21645515.2023.2178220","article-title":"Dostarlimab: From preclinical investigation to drug approval and future directions","volume":"19","author":"Cicala","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1208\/s12248-021-00624-7","article-title":"An integrated analysis of dostarlimab immunogenicity","volume":"23","author":"Lu","year":"2021","journal-title":"AAPS J."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s40265-021-01539-5","article-title":"Dostarlimab: First approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2014296","DOI":"10.1080\/19420862.2021.2014296","article-title":"Antibodies to watch in 2022","volume":"14","author":"Kaplon","year":"2022","journal-title":"mAbs"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1001\/jamasurg.2025.0242","article-title":"Molecular testing and targeted therapies in hepatobiliary cancers: A review","volume":"160","author":"Tsilimigras","year":"2025","journal-title":"JAMA Surg."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1093\/annonc\/mdx503","article-title":"Immunotherapy in pancreatic ductal adenocarcinoma: An emerging entity?","volume":"28","author":"Sahin","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s13402-019-00456-w","article-title":"Recent advances in the clinical development of immune checkpoint blockade therapy","volume":"42","author":"Ghahremanloo","year":"2019","journal-title":"Cell. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1158\/1078-0432.CCR-22-3915","article-title":"Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study","volume":"29","author":"Oaknin","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_163","unstructured":"(2026, May 13). Jemperli (Dostarlimab): EPAR. European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jemperli."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.annonc.2025.05.402","article-title":"387eTiP DOVIPA: A Phase II Study with Safety Run-in of mFOLFIRINOX, Dostarlimab, and Oral Vitamin D in Metastatic Pancreatic Cancer with Translational Research on Resistance Mechanisms","volume":"36","author":"Mitry","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2025.43.4_suppl.727","article-title":"Phase II Study of Niraparib and Dostarlimab for the Treatment of Germline or Somatic Homologous Recombination Repair Mutated (HRD) Metastatic Pancreatic Cancer","volume":"43","author":"Jazieh","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1200\/JCO.2022.40.4_suppl.564","article-title":"A Phase II Study of Niraparib and Dostarlimab with Radiation in Patients with Metastatic Pancreatic Cancer","volume":"40","author":"Parikh","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_167","unstructured":"(2026, May 15). Niraparib + Dostarlimab + RT in Pancreatic Cancer. NIH. National Library of Medicine. National Center for Biotechnology Information. ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04409002."},{"key":"ref_168","unstructured":"(2026, May 15). Niraparib and Dostarlimab in HRD Solid Tumors (DIDO). NIH. National Library of Medicine. National Center for Biotechnology Information. ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04983745."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1248\/cpb.c18-00744","article-title":"The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem. Pharm. Bull."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer","volume":"386","author":"Kim","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/gm482","article-title":"Clinical and molecular characterization of HER2 amplified-pancreatic cancer","volume":"5","author":"Chou","year":"2013","journal-title":"Genome Med."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Yajaman, D.R., Oh, Y., Trevino, J.G., and Harrell, J.C. (2025). Advancing antibody-drug conjugates: Precision oncology approaches for breast and pancreatic cancers. Cancers, 17.","DOI":"10.3390\/cancers17111792"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/13543784.2024.2376573","article-title":"Trastuzumab-Deruxtecan in Solid Tumors with HER2 Alterations: From Early Phase Development to the First Agnostic Approval of an Antibody-Drug Conjugate","volume":"33","author":"Crimini","year":"2024","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Shatzer, K., and Muller, F.L. (Trends Cancer, 2026). Repurposing payloads: Next generation of antibody\u2013drug conjugates, Trends Cancer, online ahead of print.","DOI":"10.1016\/j.trecan.2026.04.001"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"101792","DOI":"10.1016\/j.xcrm.2024.101792","article-title":"EGFR-directed antibodies promote HER2 ADC internalization and efficacy","volume":"5","author":"Gupta","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1158\/1535-7163.MCT-24-0078","article-title":"A DXd\/TLR7-agonist dual-conjugate anti-HER2 ADC exerts robust antitumor activity through tumor cell killing and immune activation","volume":"23","author":"Yue","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"104355","DOI":"10.1016\/j.critrevonc.2024.104355","article-title":"Trastuzumab Deruxtecan in Breast Cancer","volume":"198","author":"Pandiella","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(19)30097-X","article-title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: A dose-expansion, phase 1 study","volume":"20","author":"Tamura","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.2217\/fon-2021-0427","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study","volume":"17","author":"Modi","year":"2021","journal-title":"Future Oncol."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Kawczak, P., and B\u0105czek, T. (2026). Molecular Profiling and Targeted Therapeutic Strategies in Breast Cancer: Clinical Integration of HER2, CDK4\/6, and PI3K Inhibition with Trastuzumab, Abemaciclib and Alpelisib. J. Clin. Med., 15.","DOI":"10.3390\/jcm15103715"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1007\/s12094-025-03887-0","article-title":"HER2-targeted therapy in colorectal cancer: A comprehensive review","volume":"27","author":"Benli","year":"2025","journal-title":"Clin. Transl. Oncol."},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Kanwal, W., Narjis, K., Musani, S., Nancy, F., Qureshi, L., Mudasir, M., Naseem, R., Tooba, F., Yousuf, J., and Farhan, K. (2025). Exploring zanidatamab\u2019s efficacy across HER2-positive malignancies: A narrative review. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-13749-1"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","article-title":"Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: A phase 1 dose-escalation study","volume":"18","author":"Doi","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2217\/fon-2021-0550","article-title":"Trastuzumab deruxtecan for HER2+ advanced breast cancer","volume":"18","author":"Lee","year":"2022","journal-title":"Future Oncol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","article-title":"Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): Primary and updated analyses from a single-arm, phase 2 study","volume":"24","author":"Smyth","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1081\/CNV-200032974","article-title":"Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2\/neu","volume":"22","author":"Safran","year":"2004","journal-title":"Cancer Investig."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/bjc.2012.18","article-title":"Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer","volume":"106","author":"Harder","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-015-0155-z","article-title":"HER2\/neu-directed therapy for biliary tract cancer","volume":"8","author":"Javle","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Hatanaka, Y., Sasano, J., and Takizawa, O. (2026). Tumor-agnostic landscape with HER2 amplification in Japan: Real-world prevalence and implications for targeting HER2. Curr. Oncol., 33.","DOI":"10.3390\/curroncol33040195"},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Jitthiang, P., Phandthong, R., Phikulsod, P., Jirawatnotai, S., Kiatikajornthada, N., and Suwanrusme, H. (2026). Case report: Case studies evaluating anti-HER2 therapy as a tumor-agnostic strategy in rare malignancies. Front. Oncol., 16.","DOI":"10.3389\/fonc.2026.1745419"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1159\/000533866","article-title":"The potential of trastuzumab deruxtecan as a tissue agnostic drug","volume":"101","year":"2023","journal-title":"Oncology"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Makker","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_198","unstructured":"(2026, May 18). A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (DPT02). NIH. National Library of Medicine. National Center for Biotechnology Information. ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04482309."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1007\/s12325-024-02975-x","article-title":"Efficacy of trastuzumab deruxtecan in HER2-expressing solid tumors by enrollment HER2 IHC status: Post hoc analysis of DESTINY-PanTumor02","volume":"41","author":"Oaknin","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.2217\/fon-2022-0214","article-title":"Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial","volume":"18","author":"Ohba","year":"2022","journal-title":"Future Oncol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"e44094","DOI":"10.1097\/MD.0000000000044094","article-title":"Advanced cholangiocarcinoma with human epidermal growth factor receptor 2 (HER2) amplification treated with trastuzumab deruxtecan (T-DXd): A case report","volume":"104","author":"Bao","year":"2025","journal-title":"Medicine"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1080\/14796694.2025.2589996","article-title":"Trastuzumab deruxtecan in the treatment of HER2-positive gastric cancer: A comprehensive review","volume":"21","author":"Jubashi","year":"2025","journal-title":"Future Oncol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1200\/JCO.2018.77.9777","article-title":"Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: Results from a phase II basket trial","volume":"36","author":"Li","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.breast.2022.01.002","article-title":"Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer","volume":"61","author":"Nakajima","year":"2022","journal-title":"Breast"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","article-title":"Targeted therapy for advanced solid tumors on the basis of molecular profiles: Results from MyPathway, an open-label, phase IIa multiple basket study","volume":"36","author":"Hainsworth","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1158\/1078-0432.CCR-18-0531","article-title":"Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative","volume":"24","author":"Pishvaian","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.18632\/oncotarget.6498","article-title":"HER2 Genomic Amplification in Circulating Tumor DNA from Patients with Cetuximab-Resistant Colorectal Cancer","volume":"7","author":"Takegawa","year":"2016","journal-title":"Oncotarget"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1470-2045(18)30812-X","article-title":"Pembrolizumab plus Trastuzumab in Trastuzumab-Resistant, Advanced, HER2-Positive Breast Cancer (PANACEA): A Single-Arm, Multicentre, Phase 1b-2 Trial","volume":"20","author":"Loi","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus Trastuzumab and Chemotherapy for HER2-Positive Gastric or Gastro-Oesophageal Junction Adenocarcinoma: Interim Analyses from the Phase 3 KEYNOTE-811 Randomised Placebo-Controlled Trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1038\/s41467-024-46811-w","article-title":"Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer","volume":"15","author":"Bulle","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab Deruxtecan in Patients with HER2-Positive Advanced Colorectal Cancer (DESTINY-CRC02): Primary Results from a Multicentre, Randomised, Phase 2 Trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41523-026-00936-x","article-title":"Comparison of T-DXd-Associated Pulmonary Toxicity in Real-World Settings and Clinical Trials","volume":"12","author":"Udovica","year":"2026","journal-title":"npj Breast Cancer"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1007\/s10120-021-01196-3","article-title":"Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer","volume":"24","author":"Shitara","year":"2021","journal-title":"Gastric Cancer"},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"Sharma, A., Kumar, H., Paladiya, R., Sisodia, R., Bharadwaj, H.R., Mohamed, I., Alsakarneh, S., Hayat, U., Sonaiya, S., and Pinnam, H.S. (2026). Antibody-drug conjugates in gastrointestinal oncology: Clinical efficacy and inpatient toxicity management. J. Pers. Med., 16.","DOI":"10.3390\/jpm16040195"},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Chen, L., Li, G.H., and Li, C.Y. (2026). Recent advances in trastuzumab and its antibody-drug conjugates-related liver injury. Expert Opin. Drug Saf., 1\u201313.","DOI":"10.1080\/14740338.2026.2674136"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update","volume":"41","author":"Wolff","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/cpt.2096","article-title":"Population pharmacokinetics of trastuzumab deruxtecan in patients with HER2-positive breast cancer and other solid tumors","volume":"109","author":"Yin","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"e70259","DOI":"10.1002\/psp4.70259","article-title":"Population pharmacokinetics of trastuzumab rezetecan in patients with HER2-expressing or mutated advanced solid tumors","volume":"15","author":"Gao","year":"2026","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"107695","DOI":"10.1016\/j.esmoop.2026.107695","article-title":"Analysis of UGT1A1 germline variants in patients with advanced breast cancer treated with trastuzumab-deruxtecan: Results from the PROCURE Project","volume":"11","author":"Saura","year":"2026","journal-title":"ESMO Open"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s12325-017-0519-6","article-title":"Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review","volume":"34","author":"Lambert","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_221","doi-asserted-by":"crossref","unstructured":"Le Meur, C., Le Roux, P.Y., Alemany, P., Chauvelot, F., Pradier, O., Niel, C., Bellange, A., Chouaid, C., Massard, C., and Amrane, K. (2026). Case report: Complete metabolic responses to trastuzumab-deruxtecan in HER2-altered solid tumors: Two illustrative cases. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1752694"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13046-024-03143-3","article-title":"The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer","volume":"43","author":"Lee","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results from DESTINY-Breast03, a Randomised, Open-Label, Phase 3 Trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"100554","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled Analysis of Drug-Related Interstitial Lung Disease and\/or Pneumonitis in Nine Trastuzumab Deruxtecan Monotherapy Studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40264-023-01328-x","article-title":"Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel","volume":"46","author":"Chiu","year":"2023","journal-title":"Drug Saf."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s12325-024-03080-9","article-title":"Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02","volume":"42","author":"Oaknin","year":"2025","journal-title":"Adv. Ther."},{"key":"ref_227","doi-asserted-by":"crossref","unstructured":"Makker, V., Lee, J.-Y., Oh, D.-Y., Oaknin, A., Puvvada, S., Jung, L., McEwen, R., Michelini, F., and Meric-Bernstam, F. (Clin. Cancer Res., 2026). Post-Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors, Clin. Cancer Res., online ahead of print.","DOI":"10.1158\/1078-0432.c.8568739"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","article-title":"Trastuzumab Deruxtecan in Patients with Solid Tumours Harbouring Specific Activating HER2 Mutations (DESTINY-PanTumor01): An International, Phase 2 Study","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_229","unstructured":"(2026, May 15). Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients. NIH. National Library of Medicine. National Center for Biotechnology Information. ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05274048."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"25","DOI":"10.70352\/scrj.cr.25-0304","article-title":"Trastuzumab Deruxtecan Significantly Reduces Human Epidermal Growth Factor Receptor 2-Positive Pancreatic Metastasis from Advanced Breast Cancer: A Case Report","volume":"11","author":"Tanida","year":"2025","journal-title":"Surg. Case Rep."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41575-018-0005-x","article-title":"Therapeutic Developments in Pancreatic Cancer: Current and Future Perspectives","volume":"15","author":"Neoptolemos","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1158\/2159-8290.CD-18-0036","article-title":"NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer","volume":"8","author":"Heining","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"110799","DOI":"10.1016\/j.biopha.2020.110799","article-title":"microRNA-based autophagy inhibition as targeted therapy in pancreatic cancer","volume":"132","author":"Liang","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13045-020-01030-w","article-title":"Targeting hypoxic tumor microenvironment in pancreatic cancer","volume":"14","author":"Tao","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cac2.12360","article-title":"Lipid metabolism in pancreatic cancer: Emerging roles and potential targets","volume":"42","author":"Yin","year":"2022","journal-title":"Cancer Commun."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41586-025-08917-z","article-title":"Targeting PIKfyve-driven lipid metabolism in pancreatic cancer","volume":"642","author":"Cheng","year":"2025","journal-title":"Nature"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3892\/ijo.2026.5867","article-title":"Pancreatic cancer EMT-targeted therapy: Molecular mechanisms and clinical translation (Review)","volume":"68","author":"Zhang","year":"2026","journal-title":"Int. J. Oncol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"2402325","DOI":"10.1155\/sci\/2402325","article-title":"Unraveling the predictive value of HGF, RECK, CYP1B1, and ZEB2 for cancer stemness and immune microenvironment in pancreatic adenocarcinoma","volume":"2026","author":"Chen","year":"2026","journal-title":"Stem Cells Int."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"116490","DOI":"10.1016\/j.envres.2023.116490","article-title":"The bioengineered and multifunctional nanoparticles in pancreatic cancer therapy: Bioresponsive nanostructures, phototherapy and targeted drug delivery","volume":"233","author":"Saadh","year":"2023","journal-title":"Environ. Res."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"116842","DOI":"10.1016\/j.intimp.2026.116842","article-title":"Advanced platforms for antibody delivery: Overcoming biological barriers and improving therapeutic performance","volume":"182","author":"Liu","year":"2026","journal-title":"Int. Immunopharmacol."},{"key":"ref_242","doi-asserted-by":"crossref","unstructured":"Li, Y., Adams, J.P., Yang, J., Williams, A.P., Li, M., Tuohy, J., and Chen, W.R. (2026). Glycosylated chitosan inhibits pancreatic cancer metastasis by blocking the caveolin signaling pathway. Cancers, 18.","DOI":"10.3390\/cancers18091473"},{"key":"ref_243","doi-asserted-by":"crossref","unstructured":"Yadav, B., Kollur, S.P., Ali, A., Arora, P., Gupta, A., Saranraj, P., Upadhye, V.J., and Singh, P. (Discov. Oncol., 2026). Peptides as integrative modulators for clinical prognosis and targeted therapy in pancreatic cancer, Discov. Oncol., online ahead of print.","DOI":"10.1007\/s12672-026-05130-w"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"16022","DOI":"10.1038\/nrdp.2016.22","article-title":"Pancreatic Cancer","volume":"2","author":"Kleeff","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/bjs.10870","article-title":"Meta-Analysis Comparing Upfront Surgery with Neoadjuvant Treatment in Patients with Resectable or Borderline Resectable Pancreatic Cancer","volume":"105","author":"Versteijne","year":"2018","journal-title":"Br. J. Surg."},{"key":"ref_246","doi-asserted-by":"crossref","unstructured":"Janssen, Q.P., O\u2019Reilly, E.M., van Eijck, C.H.J., and Groot Koerkamp, B. (2020). Neoadjuvant Treatment in Patients with Resectable and Borderline Resectable Pancreatic Cancer. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00041"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/SLA.0000000000002600","article-title":"Predictors of Resectability and Survival in Patients with Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment with FOLFIRINOX","volume":"269","author":"Michelakos","year":"2019","journal-title":"Ann. Surg."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","article-title":"Total Neoadjuvant Therapy with FOLFIRINOX in Combination with Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial","volume":"5","author":"Murphy","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1158\/1078-0432.CCR-19-0197","article-title":"Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer","volume":"25","author":"Groot","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2018.09.022","article-title":"Circulating Nucleic Acids Are Associated with Outcomes of Patients with Pancreatic Cancer","volume":"156","author":"Bernard","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"188554","DOI":"10.1016\/j.bbcan.2021.188554","article-title":"Modeling pancreatic cancer in mice for experimental therapeutics","volume":"1876","author":"Mallya","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_252","doi-asserted-by":"crossref","unstructured":"Bai, M., Liu, M., Wang, S., Ran, M., Ye, J., Xie, Y., Zhang, C., Wang, Y., Lu, J., and Dai, F. (Mol. Cancer, 2026). Organoids in cancer therapy: Translational applications and clinical promise, Mol. Cancer, online ahead of print.","DOI":"10.1186\/s12943-026-02678-7"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): A multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"189606","DOI":"10.1016\/j.bbcan.2026.189606","article-title":"The underexplored complexity of pancreatic cancer: Early dissemination and quiescence","volume":"1881","author":"Kumar","year":"2026","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): A randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"ref_257","first-page":"ed16","article-title":"The Difficulties in Cancer Treatment","volume":"6","author":"Chakraborty","year":"2012","journal-title":"Ecancermedicalscience"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.canlet.2016.05.033","article-title":"Big Data and Machine Learning in Radiation Oncology: State of the Art and Future Prospects","volume":"382","author":"Bibault","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"115029","DOI":"10.1016\/j.jconrel.2026.115029","article-title":"Sequential gemcitabine and panobinostat-loaded albumin nanoparticle delivery via thermosensitive hydrogel in pancreatic peritoneal metastasis","volume":"395","author":"Lee","year":"2026","journal-title":"J. Control. Release"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.19.02931","article-title":"Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA\/PALB2 Mutation","volume":"38","author":"Lee","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.21.00003","article-title":"Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2","volume":"39","author":"Reiss","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1200\/JCO.19.02404","article-title":"Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors","volume":"38","author":"Yap","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"108921","DOI":"10.1016\/j.biotechadv.2026.108921","article-title":"Re-balancing immunity with CRISPR-Cas9: Novel strategies for cancer and autoimmune disorders","volume":"90","author":"Ren","year":"2026","journal-title":"Biotechnol. Adv."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"e190121","DOI":"10.1172\/JCI190121","article-title":"Simultaneous CRISPR\/Cas9-induced double-strand breaks are lethal in models of pancreatic cancer","volume":"136","author":"Teh","year":"2026","journal-title":"J. Clin. Investig."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"e206028","DOI":"10.1172\/JCI206028","article-title":"Chromosomal instability induced by CRISPR\/Cas9: Implications for pancreatic cancer therapy","volume":"136","author":"Chang","year":"2026","journal-title":"J. Clin. Investig."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"425082","DOI":"10.1200\/JCO.2023.41.36_suppl.425082","article-title":"KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Advanced Solid Tumors Harboring a KRAS G12C Mutation","volume":"41","author":"Pant","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1158\/1078-0432.CCR-23-2098","article-title":"A small molecule with big impact: MRTX1133 targets the KRAS G12D mutation in pancreatic cancer","volume":"30","author":"Wei","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMoa2600752","article-title":"Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer","volume":"394","author":"Park","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.trecan.2023.07.010","article-title":"Next Batter Up! Targeting Cancers with KRAS-G12D Mutations","volume":"9","author":"Zeissig","year":"2023","journal-title":"Trends Cancer"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s42004-025-01662-4","article-title":"Discovery of KRAS(G12D) Selective Degrader ASP3082","volume":"8","author":"Yoshinari","year":"2025","journal-title":"Commun. Chem."},{"key":"ref_272","first-page":"762","article-title":"Drugging the \u2018Undruggable\u2019 KRAS: Breakthroughs, Challenges, and Opportunities in Pancreatic Cancer","volume":"22","author":"Khan","year":"2025","journal-title":"Cancer Biol. Med."},{"key":"ref_273","unstructured":"(2026, June 27). A Study to Evaluate INCB161734 in Participants with Advanced or Metastatic Solid Tumors with KRAS G12D Mutation. ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06179160."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.drudis.2021.09.011","article-title":"Sequestosome-1\/p62-targeted small molecules for pancreatic cancer therapy","volume":"27","author":"Cuyler","year":"2022","journal-title":"Drug Discov. Today"},{"key":"ref_275","doi-asserted-by":"crossref","unstructured":"Wu, M.Y., Tang, W., Zhang, X.W., Zhang, M.N., Xu, H.D., Yu, S.R., Cheng, Y., Li, L., Chen, Y., and Liang, S. (Autophagy, 2026). PTK2\/FAK inhibition triggers TMED9-mediated protective autophagy in pancreatic cancer cell via enhancing ERGIC-ERES contact, Autophagy, online ahead of print.","DOI":"10.1080\/15548627.2026.2676079"},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"152566","DOI":"10.1016\/j.ijbiomac.2026.152566","article-title":"Comparative study on PD-L1\/ALK dual-targeted biomimetic exosomes by two preparation approaches in pancreatic cancer","volume":"367","author":"Yuan","year":"2026","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"216456","DOI":"10.1016\/j.canlet.2023.216456","article-title":"Oncolytic adenovirus as pancreatic cancer-targeted therapy: Where do we go from here?","volume":"579","author":"Yoon","year":"2023","journal-title":"Cancer Lett."},{"key":"ref_278","doi-asserted-by":"crossref","unstructured":"Xue, Y., Yu, J., Zhou, H., Chen, W., Chen, Q., Hu, L., Luo, R., Chen, Y., Wang, X., and He, X. (2026). Evaluation of translational potential of mRNA vaccine candidate antigens for pancreatic cancer: A systematic review based on clinical evidence and stratified prioritization strategies. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1803792"},{"key":"ref_279","doi-asserted-by":"crossref","unstructured":"Taing, K., Dabirian, K., and Shreenivas, A. (2026). Therapeutic cancer vaccines in gastrointestinal malignancies: Advances, challenges, and emerging strategies. Cancers, 18.","DOI":"10.3390\/cancers18091420"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"102141","DOI":"10.1016\/j.jcyt.2026.102141","article-title":"Targeting intratumoral heterogeneity in pancreatic cancer with sequential TIL infusions","volume":"28","author":"Arruda","year":"2026","journal-title":"Cytotherapy"},{"key":"ref_281","doi-asserted-by":"crossref","unstructured":"Suzuki, K., Kunisada, Y., Kuroda, Y., Kawai, H., Hurtado de Mendoza, T., Mose, E.S., Eikawa, S., Havia, H., J\u00e4rvinen, T.A.H., and Lu, C. (Cancer Res., 2026). Targeting the alphavbeta5 integrin modifies the TGF-beta-rich tumor microenvironment of pancreatic cancer, Cancer Res., online ahead of print.","DOI":"10.1158\/0008-5472.CAN-25-4223"},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"218584","DOI":"10.1016\/j.canlet.2026.218584","article-title":"The role of cancer-associated fibroblasts in various cancer drug resistance","volume":"654","author":"Dang","year":"2026","journal-title":"Cancer Lett."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in Patients with Advanced or Metastatic NTRK Fusion-Positive Solid Tumours: Integrated Analysis of Three Phase 1-2 Trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of zenocutuzumab in NRG1 fusion-positive cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.7150\/ijbs.59117","article-title":"Microorganisms in chemotherapy for pancreatic cancer: An overview of current research and future directions","volume":"17","author":"Lu","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/MOG.0000000000000765","article-title":"Consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer: Achievements and future directions","volume":"37","author":"Pandol","year":"2021","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: The LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cncr.29161","article-title":"Phase 2 Multi-Institutional Trial Evaluating Gemcitabine and Stereotactic Body Radiotherapy for Patients with Locally Advanced Unresectable Pancreatic Adenocarcinoma","volume":"121","author":"Herman","year":"2015","journal-title":"Cancer"},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.prro.2019.06.016","article-title":"Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline","volume":"9","author":"Palta","year":"2019","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3748\/wjg.v29.i2.223","article-title":"Irreversible electroporation for the management of pancreatic cancer: Current data and future directions","volume":"29","author":"Spiliopoulos","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_292","first-page":"12","article-title":"The current role of radiation in pancreatic cancer and future directions","volume":"22","author":"Hill","year":"2023","journal-title":"Clin. Colorectal Cancer"},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer","volume":"363","author":"Temel","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1200\/JCO.2016.70.1474","article-title":"Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"35","author":"Ferrell","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2017.75.2311","article-title":"Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline","volume":"35","author":"Gilligan","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11916-026-01495-3","article-title":"Applications of celiac plexus block in chronic pancreatitis or pancreatic cancer","volume":"30","author":"Ke","year":"2026","journal-title":"Curr. Pain Headache Rep."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2014.58.4904","article-title":"First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States-Based Cost-Effectiveness Analysis","volume":"33","author":"Goldstein","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/23808993.2018.1421858","article-title":"The Economic Case for Precision Medicine","volume":"3","author":"Gavan","year":"2018","journal-title":"Expert Rev. Precis. Med. Drug Dev."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1377\/hlthaff.2017.1427","article-title":"Genetic Test Availability and Spending: Where Are We Now? Where Are We Going?","volume":"37","author":"Phillips","year":"2018","journal-title":"Health Aff."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"219","DOI":"10.6004\/jnccn.2017.0022","article-title":"Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative","volume":"15","author":"Trosman","year":"2017","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_301","first-page":"115","article-title":"Economic Evaluations of Personalized Medicine: Existing Challenges and Current Developments","volume":"8","author":"Shabaruddin","year":"2015","journal-title":"Pharmgenom. Pers. Med."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1200\/EDBK_238891","article-title":"Using Big Data and Predictive Analytics to Determine Patient Risk in Oncology","volume":"39","author":"Parikh","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41571-021-00560-7","article-title":"Predicting Cancer Outcomes with Radiomics and Artificial Intelligence in Radiology","volume":"19","author":"Bera","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41575-020-0343-3","article-title":"Development of AI-Based Pathology Biomarkers in Gastrointestinal and Liver Cancer","volume":"17","author":"Kather","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/s43018-020-00146-9","article-title":"Future directions in preclinical and translational cancer neuroscience research","volume":"1","author":"Demir","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"116492","DOI":"10.1016\/j.bcp.2024.116492","article-title":"Overcoming therapy resistance in pancreatic cancer: New insights and future directions","volume":"229","author":"Patthey","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"102449","DOI":"10.1016\/j.tice.2024.102449","article-title":"Stem cell-based targeted therapy in pancreatic cancer: Current approaches and future prospects","volume":"89","author":"Mahadiuzzaman","year":"2024","journal-title":"Tissue Cell"},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"104528","DOI":"10.1016\/j.esmoop.2025.104528","article-title":"ESMO clinical practice guideline express update on the management of metastatic pancreatic cancer","volume":"10","author":"Conroy","year":"2025","journal-title":"ESMO Open"},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: Results of the Dutch randomized phase III PREOPANC trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: The A021501 phase 2 randomized clinical trial","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial","volume":"387","author":"Li","year":"2016","journal-title":"Lancet"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5521\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T01:19:55Z","timestamp":1784078395000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":311,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15145521"],"URL":"https:\/\/doi.org\/10.3390\/jcm15145521","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]}}}